晚期卵巢癌初次减瘤术中急性等容血液稀释的生存结局
该研究对前瞻性试验中接受急性等容血液稀释(ANH)的晚期卵巢癌患者进行事后分析,比较其与同期标准治疗患者的长期生存。结果显示ANH组与标准组在无进展生存和总生存上均无独立关联,减瘤后残留病灶是唯一独立不良预后因素。
要点
- ANH未独立影响晚期卵巢癌患者的无进展生存或总生存。
- 减瘤术后残留病灶是唯一独立的不良无进展生存因素。
- ANH组与标准组细胞减灭效果无显著差异。
核心结论
- 在校正潜在混杂因素后,ANH与无进展生存或总生存无独立关联。
研究设计与样本
- 对一项前瞻性试验的事后分析,比较ANH组33例与标准组360例ⅢB-ⅣB期高级别浆液性卵巢癌患者的长期生存。
主要发现
- 标准组诊断中位年龄更高(62 vs 57岁,p=0.044)且手术时间更短(446 vs 357分钟,p<0.001)。
- 细胞减灭效果(0mm、≤1cm、>1cm)在两组间无显著差异(p=0.78)。
- 多因素分析中,减瘤术后残留病灶是唯一独立不良无进展生存因素(p<0.001)。
- 总生存的显著影响因素包括术前CA125(p=0.004)、腹水(p=0.018)、残留病灶(p=0.04)和BRCA突变状态(p<0.001)。
- ANH与无进展生存(HR 0.928,95%CI 0.618-1.395;p=0.721)和总生存(HR 0.588,95%CI 0.317-1.092;p=0.093)无独立关联。
临床怎么用
- ANH可作为减少异体红细胞输注的术中管理选择,且不影响减瘤效果。
局限性
- ANH组样本量较小(n=33),事后分析设计可能影响结论推断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe oncologic outcomes after using acute normovolemic hemodilution (ANH) to reduce requirement for allogenic red blood cell transfusions (ABT) in patients undergoing primary debulking surgery (PDS) for advanced ovarian cancer. METHODS: We performed a post-hoc analysis of a recent prospective trial investigating the safety and feasibility of ANH during PDS for advanced ovarian cancer. We report long-term survival outcomes. We compared demographics, clinicopathological characteristics, survival outcomes in this cohort of Stage IIIB-IVB high-grade serous ovarian cancer patients undergoing ANH (ANH group), with a retrospective cohort of all other patients (standard group) undergoing PDS during the same time period (01/2012-04/2017). Standard statistical tests were used. RESULTS: There were no demographic or clinicopathological differences between ANH (n = 33) and standard groups (n = 360), except for higher median age at diagnosis (57 vs. 62 years, respectively; p = 0.044) and shorter operative time (357 vs. 446 min, respectively; p < 0.001) in the standard group. Cytoreductive outcomes (ANH vs. standard): 0 mm, 69.7 vs. 63.9%; gross residual disease (RD) ≤1 cm, 21.2 vs. 26.9%; >1 cm, 9.1 vs. 9.2% (p = 0.78). RD after PDS was the only independent factor associated with worse progression-free survival (PFS) on multivariable analysis (p < 0.001). Patients with BRCA mutations trended towards improved PFS (p = 0.057). Significant factors for overall survival (OS) on multivariable analysis: preoperative CA125 (p = 0.004), ascites (p = 0.018), RD after PDS (p = 0.04), BRCA mutation status (p < 0.001). After adjustment for potential confounders, ANH was not independently associated with PFS or OS [PFS: HR 0.928 (0.618-1.395); p = 0.721; OS: HR 0.588 (95%CI: 0.317-1.092); p = 0.093]. CONCLUSIONS: ANH is an innovative approach in intraoperative management. It was previously proven to decrease need for ABT while maintaining the ability to achieve complete gross resection and associated benefits.
引用
- Boerner T, Tanner E, Filippova O, et al. Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study. Gynecol Oncol. 2020. PMID: 33213899. doi:10.1016/j.ygyno.2020.10.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。